<DOC>
	<DOCNO>NCT01926483</DOCNO>
	<brief_summary>The investigator hypothesize Neoadjuvant Chemoradiotherapy beneficial treatment Patients Stage IIIA-N2 Non-Small Cell Lung Cancer , try evaluate security treatment , QoL patient influence PFS OS .</brief_summary>
	<brief_title>Phase II Trial Regimen Stage III ( N2 ) NSCLC Using Induction Treatment Followed Resection</brief_title>
	<detailed_description>Scheme : Patients receive different chemotherapy regimen depend pathological type . Squamous cell carcinoma : Docetaxel/Cisplatin concurrent radiation ( 46Gy/23f ) follow surgery , consolidate Docetaxel/Cisplatin 2 cycle . Non-squamous cell carcinoma : Pemetrexed/Cisplatin concurrent radiation ( 46Gy/23f ) follow surgery , consolidate Pemetrexed/Cisplatin 2 cycle .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>18≤Age≤65 ; ECOG performance status 0 1 ; Pathological diagnosis Stage IIIAN2 NSCLC clinically resectable N2 diagnose either mediastinoscopy , EBUS , PET/CT ; WBC≥4.0×109/l , ANC≥1.5×109/l , PLT≥100.0×109/l , Hb≥90g/l ; hepatorenal function normal ; Without history malignancy enrollment , except nonmelanoma skin cancer , situ cervical cancer ; The patient understand research sign inform consent . Female pregnancy lactate ; Female childbearing age without contraception ; With acute infection serious underlying disease ; With significant history neurological psychiatric disease，including dementia may affect ability understand sign inform consent ; Have receive treatment within last 30 day enrollment ; With uncontrollable diabetes ( blood glucose unstable treatment FBG≥8mol/L ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Stage IIIA-N2 NSCLC</keyword>
</DOC>